Manufacturer Supply High Quality Valganciclovir Hydrochloride CAS 175865-59-5 Valganciclovir HCl

• CAS No.: 175865-59-5
• Formula: C14h23cln6o5
• EINECS: 641-360-4
• Type: Synthesis Material Intermediates
• Appearance: White Powder
• Quality: Industrial
• Model NO.: TY-02AL
• Colour: White
• Package: Foil Bag
• Place: China
• Assay: 99%
• Shelf: 2 Years
• Transport Package: 25kg/Drum 5g, 100g, 500g, 1kg, 10kg, 100kg, 200kg
• Specification: 25kg/drum
• Trademark: tongyon
• Origin: China
• Production Capacity: 5000kg/Month

Product Description

 

Product name	Valganciclovir hydrochloride
CAS	C14H23ClN6O5
Appearance	white powder
Assay	99%
Storage	Cool and Protect from light

Valganciclovir hydrochloride
Product Name Valganciclovir hydrochloride

CAS 175865-59-5

MF C14H23ClN6O5

MW 390.82

EINECS 641-360-4

MOL File 175865-59-5.mol   Chemical Properties

Melting point 162-164°C
storage temp.  Keep in dark place,Inert atmosphere,2-8°C
solubility  H2O: ≥8mg/mL
form  powder
color  white to tan
InChIKey ZORWARFPXPVJLW-MTFPJWTKSA-N
CAS DataBase Reference 175865-59-5



Usage And Synthesis
Description

Valganciclovir hydrochloride, a prodrug of the antiviral ganciclovir, was launched in the US for the oral treatment of cytemegalovirus (CMV) retinitis, a sight-threatening complication in patients with AIDS. This L-Valyl ester prodrug can be prepared in three steps from the nucleoside analog ganciclovir by trimethylsilyl-protection of the amino group, coupling with N-benzyloxycarbonyl-L-valine-N-carboxyanhydride, hydrolysis with hydrochloricc acid and hydrogenolysis of the Cbz-protecting group. Valganciclovir is well absorbed and rapidly hydrolyzed to ganciclovir by intracellular esterases in the intestinal mucosal cells and by hepatic esterases. Unlike ganciclovir, valganciclovir was demonstrated to be actively transported by the intestinal peptide transporter PEPT1 in Caco-2 cells. As a consequence, its absolute bioavailability in human was 10-fold higher compared to ganciclovir (6%). In clinical trials, it was shown that a twice-daily 900 mg dose of valganciclovir resulted in similar systemic ganciclovir exposure to 5 mg/kg twice-daily intravenous injection of ganciclovir. Valganciclovir concentrations could not be quantified in most patients within three to four hours. In a randomized non-blind phase III clinical trial, oral valganciclovir (900 mg twice daily for three weeks then 900 mg once daily for one week) was as effective as intravenous ganciclovir (5 mg/kg twice daily for three weeks then 5 mg/kg once daily). Oral treatment with valganciclovir avoided catheter-related infection that sometimes occurred with intravenous ganciclovir.

GuangZhou TongYi biochemistry technology Co., Ltd is a company specializing in active pharmaceutical ingredient
(API), biology, plant extracts, chemical raw materials, fine chemicals, pharmaceutical intermediates, cosmetics raw
material. Our company has always adhered to the company philosophy of integrity, professionalism, quality first, and
customer service. With the efforts of all the company's employees, it has established long-term
and stable cooperative relations with many domestic and foreign customers, and won the unanimous trust of domestic
and foreign customers. With good comments, our company have made great progress.

Our company takes pioneering and innovative, high-quality and efficient as the code of conduct, and strives to provide
customers with efficient services,
high-quality products, and reasonable prices. We have established a customer demand-oriented, flexible, diverse and customizable service according to the different needs of different customers. Mode, and ultimately achieve the goal of
win-win.

Our company focuses on the future and the world, and will continue to devote itself to technological progress and the
development of new products in the future, hoping to work hand in hand with new and old friends at home and abroad
to create a better future.